Silence Therapeutics PLC
SLN
$18.69
Closing
▲0.59%
1D
▲7.60%
YTD
SLN
BBG00WVTHQK3
Market cap
$927.72M
52 week high
$27.72
52 week low
$6.15
Volume
18,845
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$927.72M
Analysts' Rating
BUY
Price Target (Mean)
58.25
Total Analysts
0
P/E
Operating Margin
-33.50%
Beta
1.26
Revenue Growth
-93.38%
52 week high
$27.72
52 week low
$6.15
Div. Yield
%
EPS Growth
0.00
Company Profile
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
